ReNeuron wins Breakthrough of the Year Award
ReNeuron Group plc (AIM: RENE), a UK-based global leader in the development of cell-based
therapeutics, is delighted to announce that it has won the ‘Breakthrough of the Year’ award at
last night’s 2019 European Mediscience Awards in London.
This award underlines the strong clinical development and commercial progress ReNeuron has
made over the past year. This includes positive data from the ongoing Phase 1/2a clinical trial
in Retinitis Pigmentosa and the signing of an exclusive licence agreement with Shanghai Fosun
Pharmaceutical Industrial Development Co., Ltd. for the development, manufacture and
commercialisation of ReNeuron’s CTX and hRPC cell therapy programmes in the People’s
Republic of China.
Olav Hellebø, Chief Executive Officer of ReNeuron, commented:
“We are delighted to have been awarded the Breakthrough of the Year award at the 2019
European Mediscience Awards. We are greatly encouraged by the progress we have made with
our cell therapy clinical development programmes for retinitis pigmentosa and stroke disability
over the past year and look forward to continuing to advance our clinical and business
development activities in the months ahead.”
The European Mediscience Awards is one of the largest annual gathering of private and publicly
quoted healthcare, biotech and life sciences companies in Europe. It celebrates the best in the
sector and highlights the achievements of individuals and companies operating within it.
ENDS
Contacts:
ReNeuron +44 (0) 20 3819 8400
Olav Hellebø, Chief Executive Officer
Michael Hunt, Chief Financial Officer
Buchanan (UK Media/Investor Relations) +44 (0) 20 7466 5000
Mark Court, Sophie Wills, Tilly Abraham
Argot Partners (US Media/Investor Relations) +1 212 600 1902
Stephanie Marks, Claudia Styslinger
Stifel Nicolaus Europe Limited (NOMAD and Joint Broker)
Jonathan Senior, Stewart Wallace, Ben Maddison
+44 (0) 20 7710 7600
N+1 Singer (Joint Broker)
Aubrey Powell, Mark Taylor
+44 (0) 20 7496 3000
About ReNeuron
ReNeuron is a global leader in cell-based therapeutics, harnessing its unique stem cell
technologies to develop ‘off-the-shelf’ stem cell treatments, without the need for
immunosuppressive drugs. The Company’s lead clinical-stage candidates are in
development for the blindness-causing disease, retinitis pigmentosa and for disability
as a result of stroke. ReNeuron is also advancing its proprietary exosome technology
platform as a potential delivery system for drugs that would otherwise be unable to
reach their site of action. ReNeuron’s shares are traded on the London AIM market
under the symbol RENE.L. Further information on ReNeuron and its products can be
found at www.reneuron.com.
